Post-discharge telephonic follow-up of pediatric patients affected by SARS-CoV2 infection in a single Italian pediatric COVID center: a safe and feasible way to monitor children after hospitalization

Vitangelo Clemente1,2, Costanza Tripiciano1,2*, Patrizio Moras1,2, Daniele Deriu1,2, Martina Di Giuseppe1,2, Anna Lucia Piscitelli1,2, Michela Cammerata1,2, Maria Antonietta De Ioris3, Francesca Ippolita Calò Carducci1, Stefania Bernardi1, Andrea Campana3, Patrizia D’Argenio1 and Paolo Rossi1

Abstract

Background: SARS-CoV-2 infection in children is often non severe and in the majority of cases does not require long term hospitalization, nevertheless it is burdened with social issues and managing difficulties. To our knowledge there is no literature on telephonic follow up in pediatric patients with positive PCR for SARS-CoV-2 on rhino-pharyngeal swab after discharge. The aim of the study is to describe our experience in a telephonic follow up which can allow early and safe discharge from hospital while keeping the patients under close clinical monitoring.

Materials and methods: Sixty-five children were admitted for SARS-CoV-2 infection at Bambino Gesù Pediatric Hospital COVID Center from 16th March to 3rd July. We monitored through a telephonic follow-up, using a specific survey, the patients discharged still presenting a positive PCR for SARS-CoV-2. We checked if any symptoms occurred at home until recovery, defined as two consecutive negative PCR for SARS-CoV-2 on rhino-pharyngeal swabs.

Results: During the follow up 7 patients had mild and self-limited symptoms related to SARS-CoV-2 infection, while 2 patients were re-hospitalized. One patient had Multisystem Inflammatory Syndrome in Children (MIS-C), the other patient had an increase in troponin and D-dimers.

We also monitored the average time of viral shedding, resulting in a median duration of 28 days.

* Correspondence: costanza.tripiciano@gmail.com
1Academic Department of Pediatrics (DPUO), Unit of Perinatal Infection and Congenital Infectious Diseases, Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy
2Pediatric Academic Department, University of Rome Tor Vergata, Rome, Italy
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Introduction**

In early January 2020 a novel type of Coronavirus (CoV) was identified in a patient affected by pneumonia of unknown origin [1]. The novel coronavirus (2019-nCoV) [2–4] rapidly spread worldwide, forcing the World Health Organization (WHO) to declare the outbreak as a pandemic on 11th March. The disease was named COVID-19 (Coronavirus Disease 2019) [5, 6] and the virus SARS-CoV-2 by the International Committee on Virus Taxonomy.

Italy was among the first countries in the world to be affected by the COVID-19 outbreak, with 1.2% of all patients represented by children [7–13]. According to the Italian Istituto Superiore di Sanità (ISS), the estimated overall lethality in Italian patients was 3.4%. Specifically, in pediatric setting the lethality was 0.01% between the age of 0 and 19 years [14].

Molecular-based approaches are the first line methods to confirm suspected cases of SARS-CoV-2 infection. Nucleic acid testing is the main technique for laboratory diagnosis. Other methods such as virus antigen or serological antibody testing are also valuable assays with a short turnaround time [15]. The sensitivity and specificity of rhino-pharyngeal swabs for the diagnosis of COVID-19 is not well known. It seems to be very specific, but moderately sensible (with previously published reports citing 63–78%), so a negative test does not rule out with confidence the possibility of a SARS-CoV-2 infection. The Real Time-PCR analysis of bronchoalveolar lavage fluid is the most accurate, but it could be performed easily only in patients admitted to a pediatric intensive care unit. The nasal swabs have a higher sensitivity than the pharyngeal [16].

Based on the global interest and concern about COVID-19 several studies have reviewed symptoms and characteristics of adults with SARS-CoV-2 infection [17]. Given the lower incidence in pediatric patients, there are fewer studies in this cohort [18–22].

Children mainly acquire SARS-CoV-2 infection from their family members but seem to experience a less severe form of COVID-19 disease than adults. Most of times they are asymptomatic or experience mild symptoms [23]. Frequent clinical manifestations include fever, dry cough and fatigue accompanied by other upper respiratory symptoms, such as nasal congestion and runny nose, pneumonia, dyspnea, headache and arthralgia. Moreover, the main gastrointestinal symptoms are nausea, vomiting and diarrhea [23]. An important complication of the SARS-CoV-2 infection is the Multisystem Inflammatory Syndrome in Children (MIS-C), whose clinical presentation includes fever and involvement of two or more organs, associated with laboratory evidence of inflammation. MIS-C has some similarities with Kawasaki Disease and secondary hemophagocytic lymphohistiocytosis macrophage activation syndrome [24–26].

A previous work has described the potential role of telemedicine in response to public health emergencies [27]. Telemedicine has shown to be helpful in previous outbreaks caused by SARS-CoV (severe acute respiratory syndrome–associated coronavirus) MERS-CoV (Middle East respiratory syndrome coronavirus), Ebola and Zika viruses. Ohanessian R in 2015 proposed a model for telemedicine during public health emergencies, based on tele-expertise, remote patient monitoring of contact cases, and teleconsultation for triage and isolated cases [28]. However in most countries telemedicine is not well integrated with national health care systems. For example in Italy telemedicine was not implemented by health authorities during the first phase of the SARS-CoV-2 epidemic [29].

The aim of this study is to describe our experience with telemedicine, through a telephonic follow-up model, which can allow an early and safe discharge of children with a positive PCR for SARS-CoV-2, while keeping them under close clinical monitoring.

**Materials and methods**

Sixty-five children aged between 10 days and 210 months were admitted for SARS-CoV-2 infection, confirmed by positive PCR on rhino-pharyngeal swab, at Bambino Gesù Pediatric Hospital COVID Center, from 16th March to 3rd July. Among these, 19 patients were discharged after remission of symptoms, still presenting a positive PCR on rhino-pharyngeal swab. We monitored through a telephonic follow-up all these 19 patients.

The follow up was performed during working hours by seven residents of the Bambino Gesù Children Hospital, through 2 calls per day to the patients’ parents. The calls had a variable length (from 2 to 10 min), influenced by numerous variables (e.g., patient conditions, parents’ questions, etc.). A specific survey was used (Table 1), in order to check if SARS-CoV-2-related symptoms appeared [23], if any medication was administrated to the patient and if the rhino-pharyngeal swab
was performed. In the case of the appearance of new symptoms, if necessary, the resident gave some management advices (e.g., administration of paracetamol in case of fever). The residents communicated the relevant information obtained from the phone calls to a physician of the Bambino Gesù Children Hospital COVID center.

The telephonic follow up was taken forward until two consecutive negative PCR for SARS-CoV-2 were achieved. Two consecutive PCR 24 h apart were necessary to increase the test sensitivity. All the rhino-pharyngeal swabs were performed weekly by the local health authority at patients’ home.

We tabulated the records through a Microsoft Excel Software, and we used descriptive statistics for the analysis of the data.

Results
Our cohort consisted of 19 children aged between 8 and 188 months (Table 2). Among these, 13 patients were male and 6 female. 3 of our patients presented comorbidities: 1 patient was affected by Angelmann syndrome, 1 patient had Congenital Arthrogryposis, 1 patient had Kikuchi Syndrome.

The most common symptoms were fever and cough, interstitial lung involvement on chest radiography was observed in 5 patients (Figs. 1 and 2). At admission, one patient had neutropenia, one patient had lymphopenia. All patients had normal levels of C reactive protein. Five of the 19 patients were treated with antibiotics during hospitalization, 1 patient required oxygen therapy. At discharge all patients were asymptomatic.

The average length of hospitalization of our cohort was approximately 10 days, with a range between 5 to 12 days. The time of hospitalization was in several cases influenced by non-clinical factors, including familiar and social issues; for example a domicile not adequate for isolation or difficulties of the local health authority in performing rhino-pharyngeal swab to the patients’ home.

All the 19 patients were contacted during the follow-up period and 7 of these patients presented new onset symptoms, described in literature as expression of SARS-CoV-2 infection [23], such as sore throat, conjunctivitis, cough, abdominal pain, fever, headache, myalgia and facial rash (1 for each child). Most of the symptoms were mild and healed in a few days.

Two patients were re-hospitalized for complications related to SARS-CoV-2 infection: one patient presented with MIS-C, the other patient had an increase in D-dimers and troponins 28 days after discharge. Both complications were already described in patients with SARS-CoV-2 infection [26, 30].

We also monitored the amount of time the PCR for SARS-CoV-2 took to become negative: the median of viral shedding was 28 days, with values between 15 and 59 days.

Discussion
There is little experience on follow-up in children with SARS-CoV-2 infection [31, 32]. Furthermore, to our knowledge there is no literature on the telephonic follow-up in pediatric patients with positive PCR on rhino-pharyngeal swab after discharge.

In our cohort 2 patients were re-hospitalized for the appearance of complications due to SARS-CoV-2 infections.

We compared the average of viral shedding with the data collected by De Ioris et al. and Hongmei Xu et al., and we observed that in our cohort the PCR for SARS-CoV-2 took a longer time to become negative [33, 34]. Although SARS-CoV-2 infection in the pediatric population is most of the time non severe and often asymptomatic, children’s infection is burdened with social issues and management difficulties, due to the need of familial or parental assistance during hospitalization. Early and safe hospital discharge is therefore essential in pediatric patients affected by COVID-19. A telephonic post-discharge follow-up could help to achieve a briefer hospitalization and an early detection of potential complications of the SARS-CoV-2 infection. As a matter of fact we were able to detect at an early stage the patient who presented with MIS-C, which represents a severe complication related to SARS-CoV-2 infection in children, and whose prognosis is influenced by the promptness of treatment [35].

Telehealth could allow to perform a more frequent assessment of patients’ clinical conditions rather than ambulatory follow up and could enable a decrease in the number of access to health structures during pandemic

Table 1 Post-discharge telephonic survey
The resident introduces himself (Full Name, Qualification)
Which have been the general clinical conditions of the child in the last 12 h?
Has he had hyperpyrexia in the last 12 h? If yes, which was his temperature?
Has he had breath difficulties in the last 12 h?
Has he coughed in the last 12 h?
Has he had sore throat in the last 12 h?
Has he had rhinitis in the last 12 h?
Has he had diarrhea or abdominal pain in the last 12 h?
Has he had a headache in the last 12 h?
Has he had arthralgia in the last 12 h?
Has he manifested other symptoms in the last 12 h?
Has he had another rhino-pharyngeal swab done? If so, which was the result?
Table 2 Patients’ demographic and clinical features

| Patient | Gender | Age (years) | Comorbidities | Symptoms at the onset | WBC 10^3/μL | Neutrophils 10^3/μL | Lymphocytes 10^3/μL | CRP mg/dL | Radiographic Findings: 0 = normal; 1 = interstitial lung involvement; 2 = pulmonary consolidation | Days of hospitalization | Therapy during the hospitalization | Symptoms Relapse | Days of Follow up |
|---------|--------|-------------|---------------|----------------------|-------------|---------------------|---------------------|----------|---------------------------------------------------------------------------------|---------------------|----------------------------------|------------------|-------------------|
| 1       | F      | 3.8         | NO            | Fever, febrile seizure | 8.6         | 4.15                | 3                   | 0.14     | 0                                                                                | 5                   | none                             | NO               | 48                |
| 2       | M      | 0.7         | NO            | Fever, cough          | 13          | 7.84                | 3.12                | 0.49     | 0                                                                                | 8                   | none                             | NO               | 25                |
| 3       | M      | 6.7         | Congenital Arthrogryposis, Cerebellar hypoplasia, Neurodevelopmental delay | Fever, cough, acute respiratory failure | 5.75        | 4.69                | 0.54                | 0.24     | 1                                                                 | 14                  | ceftriaxone, clarithromycin, oxygen therapy | NO               | 14                |
| 4       | M      | 13.7        | NO            | Fever, cough          | 5.44        | 2.32                | 2.26                | 0.66     | 0                                                                                | 9                   | none                             | Fever, Vomiting, Loss of appetite | 53                |
| 5       | F      | 15.7        | Immune thrombocytopenia | Fever, dyspnea       | 2.79        | 1.2                 | 1.34                | 0.37     | 1 + 2                                                                             | 6                   | hydroxychloroquine, azithromycin | Low-grade fever, Fever | 34                |
| 6       | F      | 9.7         | Angelman Syndrome | Fever, seizures       | 6.35        | 3.81                | 1.38                | 0.25     | 1                                                                                | 9                   | none                             | Fever             | 19                |
| 7       | M      | 10.9        | NO            | Fever, cough, rhinitis conjunctivitis | 5.62        | 1.34                | 2.81                | 0.03     | 0                                                                                | 6                   | none                             | Rash              | 19                |
| 8       | M      | 11.5        | Hypoacusia     | Fever, headache, arthralgia, diarrhea | 4.9         | 1.84                | 2.24                | 0.03     | 0                                                                                | 8                   | cefixime                         | Pharyngodynia, Conjunctivitis | 17                |
| 9       | M      | 10          | Recurrent otitis media | Fever, headache, arthralgia, diarrhea | 4.4         | 1.79                | 1.86                | 0.03     | 0                                                                                | 8                   | none                             | NO               | 16                |
| 10      | M      | 8.5         | NO            | No                   | 4.21        | 1.89                | 1.87                | 0.04     | 0                                                                                | 7                   | none                             | Abdominal pain, Headache, Cold sores | 24                |
| 11      | M      | 6.8         | NO            | Fever, myalgia       | 5.64        | 1.58                | 3.15                | 0.07     | 0                                                                                | 7                   | none                             | NO               | 30                |
| 12      | M      | 6.8         | NO            | Fever                | 4.43        | 1                   | 3.01                | 0.1      | 0                                                                                | 6                   | Myalgia of the lower limbs         | 11                |
Table 2 Patients’ demographic and clinical features (Continued)

| Patient | Gender | Age (years) | Comorbidities                              | Symptoms at the onset | WBC 10^3/μL | Neutrophils 10^3/μL | Lymphocytes 10^3/μL | CRP mg/dl | Radiographic Findings | Days of hospitalization | Therapy during the hospitalization | Symptoms Relapse | Days of Follow up |
|---------|--------|-------------|--------------------------------------------|-----------------------|-------------|---------------------|---------------------|-----------|----------------------|----------------------|-----------------------------------|-----------------|-------------------|
| 13      | F      | 15,3        | NO                                        | Fever, cough, anosmia | 5.48        | 2.14                | 2.1                 | 02        | 1                    | 10                   | hydroxychloroquine, azithromycin | NO              | 25                |
| 14      | F      | 2,3         | NO                                        | Cough                | 11.44       | 2.44                | 7.36                | 006       | 0                    | 14                   | none                             | NO              | 15                |
| 15      | M      | 9,6         | NO                                        | No                   | 4.36        | 1.63                | 1.67                | 006       | 0                    | 6                    | none                             | NO              | 13                |
| 16      | M      | 0,7         | NO                                        | Diarrhea             | 5.93        | 0.88                | 3.88                | 003       | 0                    | 6                    | none                             | Rash            | 28                |
| 17      | M      | 13,2        | Kikuchi Disease, Hemophagocytic Lymphohistiocytosis | Fever, cough        | 5.6         | 3.68                | 1.04                | 035       | 0                    | 23                   | none                             | NO              | 5                 |
| 18      | F      | 1,3         | NO                                        | Fever, cough        | 8.450       | 3.92                | 3.36                | 006       | 1 + 2                | 12                   | hydroxychloroquine, azithromycin | NO              | 26                |
| 19      | M      | 5,9         | NO                                        | No                   | 5.59        | 2.3                 | 2.66                | 006       | 0                    | 9                    | none                             | NO              | 25                |
Fig. 1 Patient’s chest X-ray: Interstitial involvement marked in hilar and basal left regions

Fig. 2 Patient’s lung CT: Multiple round and oval ground-glass opacities in the left lung
phases. Moreover, parents could feel more supervised and reassured through the daily conversation with the doctors of the pediatric COVID center.

In addiction briefer hospitalizations would enable a greater receptivity of the hospital during pandemic phases and would allow to reduce hospitalization related costs as described by Peong Gang Park et al. [31]

The biggest drawback of our study is the limited number of patients. Further studies will be necessary to assess the appropriate timing of calls, based on patients’ age and comorbidities.

Conclusion
Our experience highlights the importance of telephonic follow-up in attempting to reduce hospitalization time in SARS-CoV-2 infected patients still presenting a positive PCR on rhino-pharyngeal swab. Finally with this close follow up it would be possible to identify at an early stage late complications related to SARS-CoV-2 infection.

Abbreviation
MIS-C: Multisystem Inflammatory Syndrome in Children

Acknowledgements
Not applicable.

Authors' contributions
VC, CT, DR, MC, ALP, MDG, PM collected the data and performed the telephonic follow up; MADI, FICC, SB identified the eligible patients for the telephonic follow up; AC, PDA, PR supervised and coordinated the working group. The author(s) read and approved the final manuscript.

Funding
Scuola di Pediatria University of Rome Tor Vergata, Academic Department of Pediatrics (DPUO) Bambino Gesù IRCCS Pediatric Hospital.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Local ethical committee approved the study and written informed consent was obtained from all participants or legal guardians.

Consent for publication
Not applicable.

Competing interests
The authors have no conflicts of interest to declare that are relevant to the content of this article.

Author details
1Academic Department of Pediatrics (DPUO), Unit of Perinatal Infection and Congenital Infectious Diseases, Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy. 2Pediatric Academic Department, University of Rome Tor Vergata, Rome, Italy. 3Pediatric Department, Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy.
21. Shen KL, Yang YH, Jiang RM, Wang TY, Zhao DC, Jiang Y, et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition). World J Pediatr. 2020;16(3):232–9.
22. Morand A, Fabre A, Minodier P, Boutin A, Varel N, Boudure E, et al. COVID-19 virus and children: what do we know? Arch Pediatr. 2020;27(3):117–8. https://doi.org/10.1016/j.archped.2020.03.001.
23. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020;174(9):882–9. https://doi.org/10.1001/jamapediatrics.2020.1467.
24. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, MBF S, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334–46.
25. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347–58. https://doi.org/10.1056/NEJMoa2017556.
26. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel). 2020;7(7):69.
27. Lurie N, Carr BG. The role of telehealth in the medical response to disasters. JAMA Intern Med. 2018;178(6):745–6. https://doi.org/10.1001/jama.2018.1314.
28. Ohannessian R. Telemedicine: potential applications in epidemic situations. Eur Res Telemedicine/Rech Eur Télémédecine. 2015;4(3):95–8. https://doi.org/10.1016/j.eurtel.2015.08.002.
29. Ohannessian R, Duong TA, Odone A. Global telemedicine implementation and integration within health systems to fight the COVID-19 pandemic: a call to action. JMR Public Health Surveill. 2020;6(2):e18810. https://doi.org/10.2196/jmr.19810.
30. Tersalvi G, Vicenzi M, Calabretta D, Biaisco L, Pedrazzini G, Winterton D. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail. 2020;26(6):470–5. https://doi.org/10.1016/j.cardfail.2020.04.009.
31. Park PG, Kim CH, Heo Y, Kim TS, Park CW, Kim CH. Out-of-hospital cohort treatment of coronavirus disease 2019 patients with mild symptoms in Korea: an experience from a single community treatment center. J Korean Med Sci. 2020;35(13):e140. https://doi.org/10.3346/jkms.2020.35.e140.
32. Denina M, Pruccoli G, Scofaro C, Mignone F, Zoppo M, Giraudo I, et al. Sequelae of COVID-19 in hospitalized children: a 4-months follow-up. Pediatr Infect Dis J. 2020;39(12):e455–9. https://doi.org/10.1097/INF.0000000000002937.
33. Xu H, Liu E, Xie J, Smyth RL, Zhou Q, Zhao R, et al. A follow-up study of children infected with SARS-CoV-2 from western China. Ann Transl Med. 2020;8(10):623. https://doi.org/10.21037/atm-20-3192.
34. De Ioris MA, Scarselli A, Ciofi Degli Atti ML, Rava L, Smarrazzo A, Concato C, et al. Dynamic viral severe acute respiratory syndrome Coronavirus 2 RNA shedding in children: preliminary data and clinical consideration from a Italian Regional Center. J Pediatric Infect Dis Soc. 2020;9(3):366–9.
35. Consiglio CR, Cotugno N, Sardh F, Pou C, Amadio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183(4):968–81. https://doi.org/10.1016/j.cell.2020.09.016.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions